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S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves 
reactive oxygen species 
Noriko Takuwa, Sei-Ichiro Ohkura, Shin-Ichiro Takashima, Keisuke Ohtani, 
Yasuo Okamoto, Tamotsu Tanaka, Kaoru Hirano, Soichiro Usui, Fei Wang, Wa Du, 
Kazuaki Yoshioka, Yoshiko Banno, Motoko Sasaki, Ikuyo Ichi, Miwa Okamura, 
Naotoshi Sugimoto, Kiyomi Mizugishi, Yasuni Nakanuma, Isao Ishii, Masayuki 
Takamura, Shuichi Kaneko, Shosuke Kojo, Kiyoshi Satouchi, Kunitoshi Mitumori, 
Jerold Chun, and Yoh Takuwa 
Aim: Sphingosine kinase 1 (SPHK1), its product sphingosine-1-phosphate (S1P) and 
S1P receptor subtypes have been suggested to play protective roles for cardiomyocytes 
in animal models of ischemic preconditioning and cardiac ischemia/reperfusion injury. 
To get more insight into roles for SPHK1 in vivo, we have generated SPHK1-transgenic 
(TG) mice and analyzed cardiac phenotype. 
Methods and Results: SPHK1-TG mice overexpressed SPHK1 in diverse tissues, with 
a nearly twenty-fold increase in enzymatic activity. The TG mice grew normally with 
normal blood chemistries, cell counts, heart rate and blood pressure. Unexpectedly, TG 
mice with high but not low expression levels of SPHK1 developed progressive 
myocardial degeneration and fibrosis, with upregulation of embryonic genes, elevated 
RhoA and Rac1 activity, stimulation of Smad3 phosphorylation and increased levels of 
oxidative stress markers. Treatment of juvenile TG mice with pitavastatin, an 
established inhibitor of the Rho family G proteins, or deletion of S1P3, a major 
myocardial S1P receptor subtype that couples to Rho GTPases and transactivates Smad 
signaling, both inhibited cardiac fibrosis with concomitant inhibition of 
SPHK1-dependent Smad-3 phosphorylation. In addition, the anti-oxidant 
N-2-mercaptopropyonylglycine, that reduces reactive oxygen species (ROS), also 
inhibited cardiac fibrosis. In in vivo ischemia/reperfusion injury, the size of myocardial 
infract was 30% decreased in SPHK1-TG mice compared with wild-type mice.  
Conclusion: These results suggest that chronic activation of the SPHK1-S1P signaling 
results in both the pathological cardiac remodeling through ROS mediated by S1P3 and 







Sphingosine kinases (SPHKs) catalyze phosphorylation of sphingosine to produce 
pleiotropic lysophospholipid mediator sphingosine-1-phosphate (S1P), which has 
attracted much attention because of its diverse effects in a variety of cell types.1, 2 These 
include stimulation of cell proliferation, inhibition of apoptosis and regulation of cell 
shape and cell motility, among others. SPHK1 and SPHK2, the two isozymes thus far 
identified, are ubiquitously but differentially expressed during embryogenesis and in 
adult tissues.1 Previous studies3, 4 have demonstrated that either SPHK1 or SPHK2 
single knockout (KO) mice are phenotypically normal, whereas SPHK1/SPHK2 double 
KO mice are embryonic lethal with undetectable S1P levels.5 These observations 
indicate that S1P is required for mammalian embryogenesis, and is produced 
exclusively by SPHK1 and SPHK2 in vivo at least during embryonic period.  
Most of the S1P effects are mediated through members of the G protein-coupled S1P 
receptor family, which include ubiquitously expressed subtypes, S1P1, S1P2 and S1P3.6, 7 
The receptor repertoire of heterotrimeric G protein coupling to downstream signaling 
pathways, including the Rho family small GTPases, is responsible for diverse S1P 
actions.6,7 For example, S1P1 mediates S1P-directed cell migration and other biological 





mediates inhibition of cell migration through activation of Rho and resultant Rac 
inhibition via G12/13.6 S1P3 couples to Gi and G12/13, mediating activation of both Rac 
and Rho, as well as activation of phospholipase C via Gq.6 In the cardiovascular system 
S1P3 is abundantly expressed on cardiomyocytes, cardiac fibroblasts, vascular 
endothelial and smooth muscle cells, whereas S1P1 and S1P2 are mainly expressed on 
vascular endothelial and smooth muscle cells, respectively.6-12 S1P3 KO mice are 
phenotypically normal,13 however, S1P3 deletion abrogates negative chronotropic and 
hypertensive effects after intravenous administration of S1P  in vivo.14 Recent 
investigations in the cardiovascular system have suggested the involvement of the 
SPHK1-S1P signaling system in the protection of myocardium from 
ischemia/reperfusion (I/R) injury. The protective effect of S1P from I/R injury was 
abrogated by deletion of S1P3.15 Deletion of both S1P2 and S1P3, but not either alone, 
resulted in aggravation of myocardial infarction due to ischemia/reperfusion (IR) 
injury.16 Deletion of SPHK1 sensitized the myocardium to I/R injury.17 However, the 
effects of chronic activation of the SPHK1-S1P signaling system in the heart in vivo 
have not yet been addressed thus far.  
In order to evaluate the effects of endogenous overproduction of S1P on the 





overexpress functional SPHK1 isoform in diverse tissues with more than 10-fold 
increases in enzymatic activity. We found that SPHK1a TG mice showed 100% 
occurrence of cardiac fibrosis, which is associated with cardiomyocyte degeneration, 
but without cardiac hypertrophy or hypertension. The development of cardiac fibrosis 
mechanistically involved activation of the S1P3-Rho family small G protein signaling 
pathway and increased reactive oxygen species (ROS). SPHK1a TG mice also exhibited 
attenuation of myocardial infarct due to I/R injury compared with wild-type (WT) mice, 
indicating that SPHK1a overexpression has both the favorable and unfavorable effects 




2.1. Generation of SPHK1 TG Mice and S1P3 knock-out (KO)/SPHK1 TG Bigenic Mice 
We generated SPHK1 TG mice that overexpress SPHK1a in a variety of tissues under 
the universal CAG promoter (see Supplementary Materials for details). S1P3 knock-out 
(KO) mice in C57BL/6 genetic background 13 were mated with SPHK1 TG mice. All 
experiments using mice were approved by and performed according to the Guidelines 





conforms to the Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85-23, revised 1996).  
 
2.2. Measurements of SPHK Activity and Levels of S1P, 
Dihydrosphingosine-1-phosphate (DH-S1P), Sphingosine, and Ceramide  
SPHK activity in homogenates of the heart and other tissues was measured by using 
sphingosine and [γ-32P]ATP as substrates.5 Labeled lipids were analyzed as described8. 
The contents of S1P, DH-S1P, sphingosine and ceramide in the heart, serum and plasma 
were quantified as detailed in the Supplementary Materials.   
 
2.3. Experimental I/R Injury  
The heart was exposed and ischemia was achieved by ligating the left anterior 
descending coronary artery (LAD). After 30 minutes occlusion, reperfusion was 
achieved. After 24 hours of reperfusion the chest was re-opened and the LAD was 
occluded with the same suture. To estimate the ischemic area at risk (AAR), Evan’s blue 
(3%) was injected into the left ventricle, circulated and uniformly distributed throughout 
the myocardium except AAR.16 The hearts were excised and transversely sliced. The 





minutes at 37 °C to stain viable myocardium. TTC-nonstained area (infarct area) was 
determined and expressed as infarct area/AAR (%).  
 
2.4. Immunohistochemistry 
Serial horizontal sections of formalin-fixed, paraffin-embedded hearts at the level of the 
maximal diameter were subjected to anti-SPHK1a immunohistochemistry using a rabbit 
polyclonal anti-SPHK1a antibody as described in Supplementary Materials.18 
Aceton-fixed, fresh-frozen sections were also examined by indirect 
immunofluorescence by using a goat anti-desmin polyclonal antibody and a rabbit 
anti-SPHK1a antibody. 
  
2.5. Determination of the activities of Rac1 and RhoA in cardiac tissue  
Determinations of GTP-bound, active forms of Rac1 and RhoA in mouse hearts was 
performed by pull-down assay techniques as described previously9. Data are expressed 
as a percentage of the control value in the basal unstimulated state (= 100%).  
 
2.6. Detection of Oxidative Stress Markers  





urinary excretion of 8-hydroxydeoxyguanosine (8-OHdG), a stable marker of oxidative 
DNA damage, were determined by a spectrophotometrical method using BIOXYTECH 
MDA-586 assay kit (Oxis Research, Portland, OR, U.S.A.) and ELISA using an 
8-OHdG ELISA assay kit (Nikken SEIL Corporation, Shizuoka, Japan) 
 
2.7. Statistics  
All data are shown as means ± SEM. ANOVA (analysis of variance) was followed by 
Dunnette’s test to determine the statistical significance of differences between mean 
values. Unpaired t-test was performed for the comparison between two groups in Figs. 




3. Results  
3.1.Expression and activity of SPHK1, and tissue and blood levels of S1P and related 
lipids in SPHK1 TG mice 
We established two independent lines with different transgene expression levels as 





designated as TG(H), showed widespread and high expression levels of the transgene 
transcript in a variety of organs including the heart, brain, kidney, stomach and other 
tissues. The other TG lineage, TG(L), showed a moderate or low level of transgene 
expression in the heart, testis and other tissues. TG(H) and TG(L) mice were both fertile 
and apparently normal, and grew comparably with WT mice. Measurements of 
sphingosine kinase enzymatic activity and Western blot analysis in the cardiac extracts 
confirmed functional overexpression of SPHK1 in the heart of both TG(H) and TG(L) 
mice (Fig. 1A). SPHK activity in the cytosolic fraction of the heart was 4-fold and 
18-fold greater in TG(L) and TG(H) as compared to that in WT controls, respectively 
(Fig. 1A, lower). The heart tissues of TG(L) and TG(H) showed moderately and 
strongly elevated SPHK1 protein expression levels, respectively, which appeared 
comparable to respective SPHK activities, as compared with the WT heart (Fig. 1A, 
upper). Unexpectedly, however, the S1P content in the heart tissue was elevated by only 
1.6-fold in TG(H), but not in TG(L), as compared to WT (Fig. 1B). We also measured 
the sphingosine and ceramide contents in the heart and found no difference between 
TG(H) and WT littermates (Fig. 1B). S1P concentrations in the plasma or serum were 
not significantly different between WT and TG(H) mice (Fig. 1C). Dihydro-S1P level in 





Immunofluorescent staining using anti-SPHK1 and anti-desmin antibodies 
demonstrated that SPHK1 was expressed in cardiomyocytes and other types of cells 
(Fig. 2A, upper panels). SPHK1 showed two expression patterns in WT cardiomyocytes, 
which included a faint homogenous pattern and a sparsely speckled pattern. These two 
patterns of staining by anti-SPHK1 antibody was not at all observed in the heart of 
SPHK1-knockout mice (Supplementary Fig. 3), indicating that the employed antibody 
specifically detected SPHK1 protein. In cardiomyocytes of TG(H) mice, SPHK1 
expression was markedly elevated in both of these two patterns (Fig.2A, lower panels). 
SPHK1 was also expressed in blood vessels of WT and TG(H) hearts, with similar 
expression levels (data not shown). RT-PCR analysis of a panel of key molecules of the 
S1P signaling system demonstrated that mRNA expression levels of S1P1, S1P2, and 
S1P3 receptors and the enzymes, S1P phosphohydrolase 1 (SPP1), S1P lyase (SPL) and 
SPHK2, were not significantly different between WT and TG(H) hearts (Figs. 2B and 
2C). Neither the heart rate, systemic blood pressure at resting, nor heart weight to body 
weight ratio were different between TG(H) mice and their WT littermates 
(Supplementary Table I). TG(L) mice also showed normal values of these parameters. 
 






We found that both male and female TG(H) mice developed both interstitial and 
perivascular cardiac fibrosis, which were evident by 3 months and gradually progressed 
with aging (Figs. 3A and 3B).  At 3 months of age none of the WT mice showed 
detectable pathological fibrosis in the heart. In the aged population (18 months or older), 
a small population of control WT mice (13%) also showed slight fibrosis, contrasting 
with the extensive fibrosis observed in 100% of TG(H) mice. TG(L) mice showed 
virtually no cardiac fibrosis until at least 9 months of age and were not different from 
WT mice. Fibrosis was observed in both the left and right ventricles of TG(H) hearts, 
and its distribution pattern was focal and scattered in nature. In most advanced cases 
fibrosis was transmural, in part, with marked thinning of the ventricular wall (Fig. 3A, 
right). Inspections with higher magnification revealed degenerative changes, which 
included intracellular small vacuoles and mild coagulative necrosis of cardiomyocytes 
(Fig. 3C). These changes were evident especially around the focal fibrotic lesions of the 
myocardium. Immunohistochemical analysis revealed scattered foci of extremely strong 
SPHK1 overexpression in the myocardium of TG(H) mice (Fig. 3D-c). The reason for 
this non-uniform expression pattern of the SPHK1 transgene product is unknown at 





immunohistochemistry, Azan-, and HE-staining revealed that SPHK1a was expressed 
throughout the cytoplasm of affected cardiomyocytes with signs of mild degenerative 
changes, which were surrounded by collagen fibers, myocardial cells showing vacuolar 
degeneration, and a small numbers of necrotic cells (Fig. 3Dd-f). Thus, strong focal 
overexpression of SPHK1 protein was closely associated with degenerative changes and 
fibrosis. We also observed occasional calcification within the fibrotic areas. 
TUNEL-positive apoptotic cells were restricted to calcified regions (data not shown). 
We did not observe inflammatory cell infiltration in the heart nor did we find vessel 
abnormalities in the coronary vessels. We also found that TG(H) mice had normal blood 
biochemistry (Supplementary Table I) and blood cell counts including lymphocyte 
count (Supplementary Fig. 2).    
Echocardiographic analysis of 3, 6, and 12 month old TG(H) mice revealed that 
most TG(H) mice showed normal left ventricular size with no thickness of the posterior 
wall or the interventricular septum, and they maintained the normal %FS 
(Supplementary Table II). However, we did observe one 9 month-old male mouse with 
dilated left ventricle and reduced %FS, which are echocardiographic signs reminiscent 
of human dilated cardiomyopathy. 





established molecular signs of cardiac remodeling, i.e., marked upregulation of the  
embryonic genes, including atrial natriuretic peptide (ANP) (3.12- ( 3 months (m)) and 
3.12-fold (9 m) increases in TG(H) mice compared with WT mice), β-myosin heavy 
chain(β-MCH) (2.14- and 5.55-fold increases) and, to a lesser extent, brain natriuretic 
peptide (BNP) (1.13- and 1.72-fold increases) and skeletal muscle (SKM) α-actin (1.05- 
and 1.46-fold increases), as evaluated by Northern blot analysis (Supplementary Fig. 4). 
The mRNA expression levels of profibrotic factor TGF-β1 and fibrosis-marker genes 
type I and III collagens, fibronectin and α-smooth muscle actin were not different 
between SPHK1 TG(H) and WT hearts (data not shown). The expression levels of 
collagen type I α1 and α2 proteins were elevated in the SPHK1-TG heart compared 
with WT heart (Supplementary Fig. 5). 
   We evaluated the effect of SPHK1 overexpression on I/R injury. Cardiomyocyte 
death in hearts (white area in Fig. 3E) exposed to 30 min of coronary occlusion and 
followed by 24 h of reperfusion was 30% reduced in TG(H) mice compared with WT 
mice. The ischemic area at risk (AAR) (white and red areas) was not different between 
the two mouse groups. Thus, TG(H) mice are protected from myocardial I/R injury.  
 





in the Heart of TG(H) Mice 
We and others have demonstrated in various types of cultured cells that S1P regulates 
Rac1 and Rho, which are implicated in ischemic and non-ischemic cardiac 
remodeling19,20, in receptor subtype-specific manners.6 TG(H) heart tissues showed a 
1.5-fold increase in the amount of GTP-bound, active form of Rac1 as compared to 
heart tissues obtained from WT littermates (Fig. 4A, left). By contrast, the total amount 
of Rac1 protein in the heart was similar between WT and TG(H) mice (Fig. 4A, right). 
The amount of GTP-bound RhoA in the TG(H) heart tissues was 1.3-fold greater 
compared to the WT (Fig. 6B, left). The total amount of RhoA protein was similar 
between TG(H) and WT heart (Fig. 4B, right). 
Rac1 is involved in the generation of ROS in the heart,20 which in concert with other 
mechanisms, contributes to cardiac remodeling. Indeed, TG(H) heart tissues showed a 
1.5-fold increase in the content of malondialdehyde, which is a major lipid peroxide and 
a useful marker for tissue oxidative stress, as compared to WT littermates (Fig. 4C, left). 
Another oxidative stress marker, 8-OHdG, which is excised from oxidized DNA and 
secreted in the urine, showed a more than 2-fold increase over control (Fig. 4C, right). 
These results suggest that the hearts in TG(H) mice are exposed to increased oxidative 






3.4.Successful Prevention of Cardiac Fibrosis in TG(H) Mice by the HMG CoA 
Reductase Inhibitor Pitavastatin and the Anti-oxidant N-2-Mercaptopropyonylglycine 
(MPG)  
In order to gain insight into the pathophysiology of SPHK1-mediated cardiac 
remodeling, we tested whether pitavastatin, which prevents membrane recruitment and 
activation of the Rho family GTPases,21 could exert a beneficial effect on TG(H) hearts. 
The administration of pitavastatin beginning at the age of 6 weeks after birth markedly 
reduced the extent of cardiac fibrosis evaluated at 12 week old, as compared to vehicle 
control (Figs. 5A and 5B). We also examined the effect of the anti-oxidant MPG,22 and 
found that MPG was effective in inhibiting development of cardiac fibrosis (Figs. 5A 
and 5B). By contrast, the angiotensin II type 1 receptor (AT1) antagonist candesartan, 
which effectively inhibits pressure overload-induced cardiac hypertrophy and fibrosis, 
and another anti-hypertensive hydralazine, failed to inhibit fibrosis at doses that 
effectively and similarly lowered blood pressure (Figs. 5A and 5B).  
 
3.5. S1P3 Deletion Partially Inhibits Cardiac Fibrosis in TG(H) Mice  





fibroblasts.8, 10 Hence, we evaluated whether S1P3 signaling was involved in cardiac 
fibrosis induced by SPHK1a overexpression, by generating S1P3KO/TG(H) mice. 
Deletion of S1P313 resulted in a substantial reduction in the area of cardiac fibrosis as 
compared with S1P3WT(+/+)/TG(H) littermates (Figs. 6A and 6B), indicating that S1P3 
receptor signaling is at least partially involved in SPHK1-dependent cardiac remodeling 
and fibrosis. We examined activation of Smad3, which is a downstream effector of 
TGFβ and transactivated by S1P3,23,24 in the heart. In the background of S1P3+/+, Smad3 
phosphorylation in TG(H) heart was 50% increased compared with WT heart (Fig. 6C). 




The present study demonstrates for the first time that chronic increased SPHK1 activity 
can induce cardiac fibrosis in vivo. Despite constitutive high enzymatic activity of 
SPHK1 in a variety of tissues including platelets, which have been believed to be one of 
major sources of plasma S1P,1 SPHK1 TG(H) mice showed normal plasma and serum 
S1P levels, and only moderate increases in heart S1P level (Figs. 1B and 1C). These 





homeostasis of blood and tissue S1P levels in vivo. In the heart tissue, the levels of 
ceramide and sphingosine, the precursors of S1P, were not significantly different 
between WT and TG(H) mice, suggesting an increased turnover of sphingolipid 
metabolism in the transgenic heart, in which increased production of S1P by SPHK1 
overexpression is balanced by increased degradation of S1P. Since mRNA expression 
levels of the S1P degrading enzymes, SPL and SPP1, were similar between WT and 
TG(H) mice (Figs. 2B and 2C), it is possible that these enzymes have a substantial 
intrinsic activity, or, alternatively, might be functionally upregulated by an excess 
amount of S1P, resulting in a homeostatically maintained S1P level that allows survival 
of mice despite increased SPHK activity. Particularly, it is an interesting possibility that 
SPL might play a major role in homeostasis of tissue and blood S1P levels in the face of 
increased SPHK activity, because a recent study25 showed that deletion of SPL resulted 
in marked increases in tissue and blood S1P levels. 
Chronic overexpression of SPHK1 resulted in the development of degenerative 
changes and interstitial fibrosis in the myocardium in the naïve heart, which advances 
with age (Fig. 3). Fibrosis was observed in 100% of the TG(H) hearts but not at all in 
TG(L) heart, indicating that cardiac fibrosis in SPHK1 TG mice was gene 





same age throughout the observation period of 15 months, indicating that this cardiac 
fibrosis is not associated with normal aging. Despite degeneration and fibrosis, the 
cardiac function in most of TG(H) hearts was maintained at least until 12 months after 
birth (supplementary Table II), and the lifespan of the TG(H) mice were not shorter than 
the WT littermates (N. Takuwa, unpublished observation). However, we cannot exclude 
the possibility that TG(H) mice might develop diastolic dysfunction due to cardiac 
fibrosis because echocardiography is not optimal to detect diastolic dysfunction.26 We 
observed that one 9 month old TG(H) mouse showed marked ventricular dilation 
reminiscent of human dilated cardiomyopathy. The ventricular dilation may have 
represented a decompensated stage of cardiac remodeling under sustained oxidative and 
possibly additional stresses in this SPHK1 TG(H) mice. 
The development of SPHK1-mediated cardiac fibrosis was strongly inhibited in 
S1P3 KO mice (Fig. 6). It is likely that S1P locally produced by overexpressed SPHK1 
acts in a paracrine fashion on S1P3, which is abundantly expressed in cardiomyocytes 
and fibroblasts among S1P receptors, and mediates cardiac fibrosis.10,14 The Smads, the 
major downstream signaling molecules of TGF-β, constitute the signaling pathways to 
induce tissue fibrosis through activating multiple downstream pathways.19,24 Deletion of 





(Fig. 6C). It was recently demonstrated in several other cell types including fibroblasts, 
keratinocytes, and mesangial cells that the Smad signaling pathway is trans-activated by 
S1P receptors including S1P3.23, 24 Particularly, S1P3 stimulation in fibroblasts induced 
differentiation into myofibroblasts via trans-activation of Smad3.23 The present 
observations together with these previous findings suggest the possibility that 
stimulation of Smad3 in SPHK1-TG heart may be brought about by trans-activation of 
TGFβ signaling pathway by S1P-S1P3 and involved in cardiac fibrosis. Further study is 
required to substantiate the role of the Smad pathway in S1P-S1P3 mediated cardiac 
fibrosis. Our observation that TGF-β1 mRNA level in the heart was not increased in 
SPHK1-TG mice compared with WT mice lends the support to the notion that Smad3 
may be trans-activated in SPHK1-TG heart. It is possible that degradation process of 
collagens might be suppressed via S1P3 receptor-mediated Smad trans-activation in the 
heart of SPHK1-TG mice as suggested in mesangial cells,24  which is consistent with 
our observations that there was no increase in the mRNA levels of collagens and 
fibronectin in TG(H) heart. 
As the molecular mechanisms for S1P-mediated cardiac fibrosis, we focused on Rho 
family GTPases, which contribute to cardiac fibrosis through more than a single 





activated by S1P receptors in a receptor subtype-specific manner.6 We detected a modest 
increase in the activities of Rac and Rho in the TG(H) heart as compared to WT 
littermates (Fig. 4). Consistent with the notion that the Rho family GTPases are 
involved in the pathogenesis of cardiac fibrosis in the TG(H) heart, pitavastatin, which 
inhibits membrane targeting of both Rac1 and RhoA,21 strongly inhibited the 
development of fibrosis (Fig. 5). Rac is an upstream regulator essential for ROS 
production, which is implicated in cardiac fibrosis and remodeling.19, 20, 27 The levels of 
oxidative stress markers were increased in TG(H) mice (Fig. 4C). Moreover, the 
administration of the anti-oxidant MPG inhibited fibrosis (Fig. 5). It is reported that 
SPHK is also involved in ROS production in vascular smooth muscles.8 The 
morphological and pathophysiological analyses of SPHK1-TG mice (Supplementary 
Table I and other data) suggested that cardiac remodeling in the TG(H) heart was not 
secondary to hypertension, ischemic heart disease, or other metabolic disorders. These 
results collectively suggest that S1P3-mediated Rho GTPase activation, Smad activation, 
and ROS production in the heart in concert result in cardiac fibrosis when S1P level in 
the heart is elevated. However, we cannot unequivocally preclude the possibility that the 
effects of SPHK1 overexpression in other tissues in part contribute to the observed 





Spiegel and her colleagues28 first proposed that SPHK1 and its product S1P act 
inside of cells to mediate mitogenic and anti-apoptotic effects. Recent studies29,30 
showed in SPHK1-/-SPHK2+/- mice or SPHK1-/- mice that marked accumulation of 
sphingosine and dihydrosphingosine, but not a decreased S1P level, resulted in 
increased cell death in the deciduum of pregnant mice and reduced tumor size in the 
spontaneous intestinal polyps, respectively. In the latter report,30 deletion of the S1P2 or 
S1P3 receptor did not alter size of tumors. These observations suggested that 
intracellular accumulation of pro-apoptotic sphingosine, but not S1P receptor signaling, 
led to inhibition of cell proliferation or increased cell death. Our data rather suggest that 
cardiac fibrosis in SPHK1 TG mice is a S1P receptor-mediated event. Thus, the roles of 
sphingolipids in the regulation of cell survival and proliferation may be different, 
depending on cell types and the context of impairment of sphingolipid metabolism.  
Recent investigations8 (for review) in the cardiovascular system have showed the 
cardio-protective role of the S1P signaling system in myocardial I/R injury. SPHK1 was 
suggested to be a key enzyme by the observation that deletion of SPHK1 aggravated I/R 
injury in an in vitro Langendorff apparatus.17 In vivo studies using S1P receptor-deleted 
mice15,16 showed that the cardio-protective effects of the S1P signaling system in 





Consistent with these previous investigations, the present study showed that chronic 
overexpression of SPHK1 in the mouse heart is cardio-protective against myocardial 
infarction due to I/R injury in vivo (Fig. 3E). Thus, SPHK1 overexpression has both the 
unfavorable fibrosis-promoting and favorable cardio-protective effects.  
Immunofluorescent detection revealed two types of SPHK1 expression patterns, 
including a faintly homogenous pattern and a sparsely speckled pattern in both 
SPHK1-TG and WT mice (Fig. 2A). The speckled expression pattern may suggest that 
SPHK1 is present not only diffusely in the cytoplasm but also in the subcellular 
locations, most likely in the subcellular organella. In addition, the SPHK1 TG(H) mouse 
heart showed focal regions of strong overexpression of SPHK1 in the myocardium (Fig. 
3D). At present, the reason for the latter expression pattern of the transgene product is 
not known. TG mice have been back-crossed to C57BL/6 mice more than 9 times, 
which excludes the possibility of genetic chimerism of the TG mice adopted in the 
present study. Whatever the reason for the uneven overexpression of the transgene 
product in the myocardium, our observation that severe pathological changes occur in 
the regions with SPHK1 overexpression strongly suggests that locally expressed 






In summary, the present study demonstrated for the first time that transgenic 
overexpression of SPHK1a in heart tissue led to chronic, progressive myocardial 
degeneration and fibrosis in mice while it conferred a protective effect on the 
myocardium against I/R injury. The SPHK1-dependent cardiac fibrosis in TG(H) mice 
likely involves the S1P3-Rho family small G protein signaling pathway and downstream 
ROS production and subsequent TGF-β activation. These findings are consistent with 
the demonstration of other lysophospholipid receptors in fibrosis.31  The relevance of 
these observations in transgenic mice to human cardiac fibrosis of the ischemic, 
hypertensive, and other origins deserves further investigation.  
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Fig. 1.  Functional expression of SPHK1a in transgenic mice. (A) Functional 
expression of SPHK1a protein in TG(L) and TG(H) heart tissue. Cytosolic fractions of 
the heart homogenates (n=3) were subjected to in vitro SPHK assay. Left, The results 
are expressed as % of the control value obtained from WT mice. *p<0.05, **p＜0.01. 
Right, Western blot analysis of SPHK1a protein (indicated by an arrowhead) in the 
heart. (B) S1P, sphingosine, and ceramide contents in the heart of WT and TG(H) mice. 
Data represent the mean ± S.E. obtained from the numbers of animals shown in 
parenthesis at the bottom. **p＜0.01  (C) S1P and dihydro-S1P (DH-S1P) levels in 
plasma and serum of WT and TG(H) mice. 
 
Fig. 2. Expression of SPHK1 protein and related molecules in heart. (A) 
Immunofluorescent analysis of desmin (red) and SPHK1a (green) in cardiac tissues of 
WT (upper panel) and TG(H) (lower panel) mice. (B) Representative results of RT-PCR 
analysis performed in triplicate of the S1P1, S1P2, and S1P3 receptors, SPHK1a, SPHK2, 
SPP, SPL. β-Actin was adopted as an internal control. (C) Quantification of the results 






Fig. 3. Development of cardiac fibrosis in TG(H) mice. (A) Representative 
photographs of Azan-stained horizontal sections of the heart from 3, 9, and 15 month 
old TG(H) mice. Inset, magnification of a region of transmural fibrosis. (B) Quantified 
data of cardiac fibrosis. Four or five mice in each group were analyzed. (C) HE-stained 
section of a TG(H) mouse heart, showing vacuolar changes (arrows) and mild 
coagulative necrosis (arrowheads) of cardiomyocytes around the fibrotic area 
(asterisks). Cardiac fibrosis was not observed ain TG(L) mice until the age of 9 months. 
(D) Comparison of immunohistochemical staining of the SPHK1 protein (brown color, 
a and c) and fibrosis in Azan staining (blue color, d and f) and HE staining (e) in a 
TG(H) mouse heart. (E) Myocardial infarct in WT and TG(H) mice after 
ischemia/reperfusion (I/R). Upper: representative photomicrographs of ventricles. Blue 
areas, non-ischemic tissue; white areas circumscribed with the red line, infarcted area; 
red areas circumscribed with the yellow line except white area, salvaged tissues. The 
red and white areas are the area at risk (AAR). Lower: quantified infarct areas corrected 
for AAR. **p＜0.01  
 
Fig. 4.  TG(H) heart tissue showed increased activities in Rac and RhoA small 





active forms of Rac (A) and RhoA (B) in the heart of WT and TG(H) mice were 
determined by pull-down assay technique and normalized by total GTPase amounts. 
*p<0.05, **p＜0.01. Total Rac and RhoA protein levels were not different from WT 
control. (C) TG(H) mice showed increased levels of oxidative stress markers. 
Malondialdehyde content in the heart tissue (left) and urinary secretion of 8-OHdG 
(normalized by creatinine concentration, right) were quantified and compared between 
TG(H) and WT mice. Data represent the mean ± S.E. obtained from 5 to 9 mice. 
*p<0.05, **p＜0.01. 
 
Fig. 5.  Preventive effects of an HMG CoA reductase inhibitor (pitavastatin) and 
an anti-oxidant (MPG), but not an angiotensin II type 1 receptor antagonist 
(TCV116), against development of cardiac fibrosis.  (A) Representative photographs 
of Azan stained horizontal sections of the heart obtained from TG(H) mice that received 
pitavastatin, MPG, TCV-116, hydralazine, or vehicle. (B) Quantitative analysis of 
fibrotic area expressed as the percentage of the total cross sectional area. TG(H) mice at 
the age of 6 weeks were randomly assigned to either of the treatment groups, each 
consisting of 5 to 7 mice. Medical intervention was continued until 12 weeks old. 





blood pressure, did not have any effect on fibrosis by itself. **p＜0.01. 
 
Fig. 6. Deletion of the S1P3 receptor reduced the development of cardiac fibrosis 
and stimulated Smad3 phosphorylation in TG(H) mice. (A) Representative 
photographs of Azan stained horizontal sections of the heart obtained from WT/TG(H) 
or S1P3KO/TG(H) mice. (B) Quantitative analysis of the fibrotic area expressed as a 
percentage of the total cross sectional area. Littermate S1P3WT/TG(H) and 
S1P3KO/TG(H) mice  (n=5) at the age of 16 weeks were subjected to analysis. (C) 
Western blot analysis of Smad3 phosphorylation. The upper and lower panels show 
phosphorylated Smad3 (p-Smad3) and total Smad2/3, respectively. The bands indicated 
by the asterisks on the blots most likely represent non-specific or degradation products 






Materials and Methods 
Generation of SPHK1 Transgenic (SPHK1 TG) Mice and S1P3 knock-out 
(KO)/SPHK1 TG Bigenic Mice 
SPHK1 TG mice that overexpres SPHK1a isoform under the universal CAG promoter 
was generated as described previously1. TG mice were back-crossed to C57BL/6J more 
than 9 times. SPHK1 TG mice was identified by genotyping with the PCR using the 
forward PCR primer 5’-AGGGGCGTGTTTTCTGTGGAT-3’ and the reverse primer 
5’-TGGCAGAGGGAAAAAGATCTC-3’. PCR comprised 30 cycles of 0.5 min at 94°C, 
0.5 min at 60°C, and 0.5 min at 72°C. The PCR product consisted of 261 bp. S1P3 
knock-out (KO) mice in C57BL/6 genetic background were described previously2. 
Matings between S1P3 KO and SPHK1 TG mice resulted in generation of 
S1P3+/-/SPHK1TG and S1P3+/-/WT siblings with the expected 1:1 ratio. 
S1P3+/-/SPHK1TG and S1P3+/-/WT siblings were then crossed to obtain 
S1P3+/+/SPHK1TG and S1P3-/-/SPHK1TG littermates. The mice were housed in 
conventional conditions with free access to water and regular food in an air-conditioned 
room.   
 
Northern Blot analysis and RT-PCR analysis 
CVR-2008-1173R2 
Total RNA was obtained from the cardiac apex as previously described3. The expression 
level of SPHK1 mRNA was analyzed by Northern blot analysis using a 459 bp 
EcoRI-HinCII fragment of pCAGGS-SPHK1a1 as a probe as described previously3. 
Probes for atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), β−myosin 
heavy chain (β-MHC), skeletal muscle (SKM) α-actin and glyceralaldehyde 
3-phosphate dehydrogenase (GAPDH) as an internal control were obtained as 
described3. The radioactivities of corresponding bands were quantified by using Fuji 
BAS bioimage analyzer 2000 (Fuji Film, Tokyo, Japan) and expressed as a fold-increase 
above the control which is expressed as 1.0. RT-PCR analysis of S1P1, S1P2, S1P3, and 
SPHK1 were performed as described by Ryu et al.4, that of SPHK2 was performed as 
described by Mizugishi et al. , and SPP and SPL according to the method described by 
Pettus et al . The forward and reverse primers for TGF-β1 were 
5
6
5’-CCAAAGACATCTCACACAGTA-3’ and 5’-TGCCGTACAACTCCAGTGAC-3’. 
 
Western Blot Analysis  
For detection of SPHK1a protein in the heart, the homogenates were prepared in 
ice-cold buffer A containing 250 mM sucrose, 10 mM Tris/HCl (pH 7.5), 5 mM MgCl2, 
2 mM EGTA, 1 mM dithiothreitol, 1 mM Na3VO4, 20 mM NaF, 1 mM 
phenylmethylsulphonylfluoride, and 20 mg/ml each of leupeptin and aprotinin. After 
CVR-2008-1173R2 
centrifugation at 3,000 x g the supernatant devoid of nuclei and debris were centrifuged 
at 10,000 x g for 10 min to obtain a supernatant post-mitochondrial fraction, which was 
further centrifuged at 100,000 x g for 60 min at 4 °C to separate cytosolic and 
microsomal fractions. Cytosolic protein was dissolved in Laemmli’s sample buffer 
followed by 10% SDS-polyacrylamide gel electrophoresis and Western blot analysis 
using a rabbit polyclonal anti-SPHK1a as described7. Rabbit polyclonal 
phospho(Ser423/425)-Smad3 antibody (#9514) and mouse monoclonal Smad2/3 
antibody (#610843) were purchased from Cell Signaling and BD BioSciences, 
respectively. In Western analysis of phospho-Smad3, the primary and secondary 
antibodies was diluted in Can Get Signal-Solution 1 and -Solution 2 (TOYOBO, Osaka, 
Japan), respectively, followed by visualization using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific, Rockland, IL, U.S.A.). For 
detection of procollagen type I α1 and α2 polypeptides, the cardiac homogenates (90 µg 
protein) prepared by using the buffer A was separated on 8% SDS-PAGE, followed by 
detection using goat polyclonal anti-type I α1 (#sc-8783) and type I α2 (#sc-8786) 
antibodies (Santa Cruz). 
 
 
Measurements of SPHK Activity and Levels of S1P, Dihydro-S1P, Sphingosine, and 
CVR-2008-1173R2 
Ceramide  
SPHK activity in the heart and other tissues was measured as described previously8. In 
brief, the cardiac apex was dissected, rinsed in ice-cold phosphate-buffered saline, snap 
frozen in liquid nitrogen, and then homogenized in ice-cold sphingosine kinase buffer 
which contained 50 mM Tris (pH 7.5), 10 % glycerol, 1 mM β-mercaptoethanol, 1 mM 
EDTA, 1 mM sodium orthovanadate, 40 mM β-glycerophosphate, 15 mM NaF, 10 
µg/ml each of leupeptin and aprotinin, 1 mM phenylmethylsulfonyl fluoride, and 0.5 
mM 4-deoxypyridoxine. After centrifugation at 10, 000 x g, the supernatant was 
ultracentrifuged at 100, 000 x g for 30 min to obtain the cytosolic fraction. Protein (15 
µg) was incubated with 50 µM sphingosine (prepared in mixed micelles in the presence 
of Triton X-100), 10 µCi of [γ-32P]ATP (1 mM) and 10 mM MgCl2. Labeled lipids were 
extracted and resolved by thin-layer chromatography as described previously8.  
S1P content in the heart, serum and plasma, and sphingosine content in the heart 
were quantified as described previously9. The heart tissue was homogenized in 1 M 
NaCl-25 mM HCl solution and extracted by sequentially adding equal volumes of 
methanol and chloroform, and 1/10 volume of 3 N NaOH. After phase separation, the 
organic phase was re-extracted with methanol-1 M NaCl (1:1, vol/vol). Mass levels of 
S1P and sphingosine, which were recovered in combined aqueous and organic fractions, 
CVR-2008-1173R2 
respectively, were measured5.  
Levels of S1P and dihydro-S1P (DH-S1P) in the plasma and serum were also 
quantified by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry using Voyager System 4058 (Applied Biosystems) as described10, with 
similar results. DH-S1P was detected at m/z 968.  However, second stable isotopic ion 
of S1P, (M+2) ion of S1P, appears at the same mass (m/z 968).  Therefore, actual 
intensity of DH-S1P was calculated by subtracting the intensities of (M+2) ion of 
S1P.  The amounts of DH-S1P were determined based on the ratio between its actual 
intensity and the intensity of C17 S1P as an internal standard. Quantitative measurement 
of ceramide species was made on lipid extracts obtained by the methods of Bligh and 
Dyer, using a triple-quadrupole mass spectrometer (Finnigan MAT TSQ 7000) as 
previously described11. Each sample was analyzed in duplicate. 
 
Measurements of Heart Rates and Blood Pressure in Conscious Mice  
Heart rate and systolic and diastolic blood pressure of conscious mice were measured by 
a tail cuff method using Softron BP98A (Softron Co. Tokyo)1. Prior to the 
measurements, the mice were trained to become accustomed to the tail cuff method by 
undergoing trial sessions in one week. At least seven measurements were performed on 
individual mice to obtain the mean values. Before each experiment mice were kept at 37 
CVR-2008-1173R2 
°C for 10 min to avoid any vasoconstriction caused by environmental stress.  
 
Echocardiography   
Mice were anesthesized with pentobarbital (60 mg/kg) and echocardiography was 
performed using an ultrasonography (Agilent Technology SONOS5500). A 12-MHz 
linear ultrasound transducer (S12) was applied to the depiliated left anterior chest wall. 
M-mode measurements of left ventricular (LV) internal diameters, interventricular 
septal thickness, and posterior wall thickness were taken for more than five beats and 
averaged. LV end-diastolic diameter (LVEDD) was measured at the time of apparent 
maximal LV diastolic dimension. LV end-systolic diameter (LVESD) was measured at 
the time of the most anterior systolic excursion of the posterior wall. Percent fractional 
shortening (%FS) was calculated as (LVEDD-LVESD)/LVEDD x 100. 
 
Experimental Ischemia/Reperfusion (IR) Injury and Myocardial Infarction 
Mice were anesthetized by intraperitoneal injection of pentobarbital sodium (65mg/kg). 
A positive-pressure respirator was used with 65% oxygen during the surgical procedure. 
Mice were kept warm using heating pads. The heart was exposed by left thoracotomy 
between the ribs (third intercostals space). Ischemia was achieved by ligating the left 
anterior descending coronary artery (LAD) using a 7-0 nylon suture with a 1mm silicon 
CVR-2008-1173R2 
tubing placed on top of LAD. Myocardial ischemia was confirmed by ECG change (ST 
elevation). After 30 minutes occlusion, the silicon tubing was removed to achieve 
reperfusion and hearts were hervested after 24 hours of reperfusion. After I/R, mice 
were reanesthetized and intubated, and the chest was opened. The LAD was occluded 
with the same suture, which had been left at the site of the ligation. To estimate the 
ischemic area at risk (AAR), Evan’s blue (3%) was injected into the left ventricule, 
circulated and uniformly distributed without risk area.12 After arresting the heart at the 
diastolic phase by KCl injection, hearts were quickly excised and sliced into 1-mm thick 
cross sections. The heart sections were incubated with a 2% triphenyl tetrazolium 
chloride for 10 minutes at 37 degree. TTC stained area (ischemic and viable area), TTC 
negative stained are (infarct area), and total LV area from both sides of each section 
were measured using Image J (NIH, USA), and each sections were multiplied by the 
weight of the section and then totaled from all sections. AAR/LV, infarct are/LV, and 
infarct area/AAR were expressed as a percentage. 
 
Histological Analysis, Immunohistochemistry, and Immunofluorescence 
Wild-type mice, SPHK1-TG mice, and SPHK1-KO mice (kindly supplied by Dr. 
Richard Proia in National Institute of Diabetes and Digestive and Kidney Diseases, 
CVR-2008-1173R2 
Bethesda, MD, U.S.A.) were euthanized by intraperitoneally injecting an excess dose of 
pentobarbital. Serial horizontal sections of formalin-fixed, paraffin-embedded hearts at 
the level of the maximal diameter were subjected to anti-SPHK1a 
immunohistochemistry, Azan staining (for detection of fibrosis), and HE staining. 
Immunohistochemical detection of SPHK1a was performed using a rabbit polyclonal 
anti-SPHK1a antibody as described previously7. Aceton-fixed, fresh-frozen sections 
were also examined by indirect immunofluorescence by using a goat anti-desmin 
polyclonal antibody and a rabbit anti-SPHK1a antibody. 
  
Determination of the Activities of Rac1 and RhoA in Cardiac Tissue  
Determinations of GTP-bound, active forms of Rac1 and RhoA in the mouse heart was 
performed by pull-down assay techniques as described previously14. In brief, the heart 
homogenates were prepared in an ice-cold lysis buffer and 10,000 x g supernatant was 
incubated at 4 oC with either GST-PAK (for active Rac1) or GST-rhotekin (for active 
RhoA) immobilized on glutathione-Sepharose beads for 40 min. The proteins bound to 
Sepharose beads, as well as total Rac1 or RhoA derived from a portion of the same cell 
lysate, were solubilized with Laemmli’s sample buffer and subjected to electrophoresis 
and Western blot analysis, using mouse monoclonal anti-Rac1 and anti-RhoA antibodies 
CVR-2008-1173R2 
as described13. The corresponding bands were densitometrically quantitated by using the 
Quantity One Image Analyzing System (Bio-Rad). Data are expressed as a percentage 
of the control value in the basal unstimulated state (= 100%).  
 
Detection of Oxidative Stress Markers  
The content of malondialdehyde, a major lipid peroxidation product, in heart tissue was 
spectrophotometrically quantitated by using BIOXYTECH MDA-586 assay kit (Oxis 
Research, Portland, OR) according to manufacturer’s instructions. Urinary excretion of 
8-hydroxydeoxyguanosine (8-OHdG), a stable marker of oxidative DNA damage, was 
measured in the urine by using an 8-OHdG ELISA assay kit (Nikken SEIL Corporation, 
Shizuoka, Japan), according to the manufacturer’s instructions. The results were 
normalized on the basis of creatinine concentration that was measured by Jaffe reaction. 
 
Chronic Treatment of Mice with Pharmacological Agents  
Six week-old TG(H) and WT littermates were randomized to 6 weeks of treatment with 
either of the followings:  pitavastatin (1 mg/kg/day in drinking water) kindly donated 
from the Kowa Pharmaceutical Company (Nagoya, Japan), MPG (100 mg/kg/d by daily 
i.p. injections) (Sigma)14, their vehicle control (Dulbecco’s phosphate buffered saline), 
CVR-2008-1173R2 
TCV-116 (10 mg/kg/day in drinking water) generously supplied by Takeda 
Pharmaceutical Company (Osaka, Japan), its hypotensive control, hydralazine (10 
mg//kg/day in drinking water) (Sigma). After treatment the mice were euthanized by an 
excess dose of pentobarbital and the extent of cardiac fibrosis was analyzed using the 
NIH Image J software.  
 
Statistics  
All data are shown as mean ± SEM. ANOVA (analysis of variance) was followed by 
Dunnette test to determine the statistical significance of differences between mean 
values. Unpaired t-test was performed for the comparison between two groups in Figs. 
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Table I. Heart/ body weight, heart rate, blood pressure, and blood biochemistry 
 WT SPHK1 Tg(H) 
Heart/ BW (mg/g) 4.88±0.13 (8) 4.83±0.19 (7) 
Heart rate (beats/min) 644±13 (8) 637±15 (7) 
Systolic BP (mmHg) 97±2 (8) 101±3 (7) 
Diastolic BP (mmHg) 56±2 (8) 59±3 (7) 
Serum total chol (mg/dl) 86.0±13.4 (4) 75.3±3.8 (3) 
Serum triglyceride (mg/dl) 82.7±24.1 (4)  65.6±19.3 (3) 
Serum glucose (mg/dl) 187±16 (4) 209±28 (3) 
20 weeks old male SPHK1 Tg (H) and wild-type (WT) littermates were analyzed. 
The values are means±S.E.  BW, body weight; BP, blood pressue; chol, cholesterol. 
The numbers in the parentheses indicate the numbers of analyzed mice. 
CVR-2008-1173R2 
 
Mice of indicated ages were subjected to echocardiographic analysis. LVEDD, left ventricular end 
diastolic diameter, LVESD, left ventricular end systolic diameter; %FS, percent fractional shortening; 
IVSS, interventricular septal thickness in systole; IVSD, interventricular septal thickness in diastole; 
PWD, posterior wall thickness in diastole; PWS, posterior wall thickness in systole. Data are expressed as 
means ± S.D. Numbers of mice in each group are given in parenthesis. ns, not significant. EDD, ESD, 







Table II. Echocardiographic analysis of WT and SPHK1-Tg (H) hearts 
  3 months  6 months   12 months 
        
  WT TG  WT TG   WT TG 
  n=8 n=5  n=6 n=6   n=6 n=3 
EDD  3.27±0.04 3.29±0.04  3.44±0.07 3.39±0.10   3.62±0.02 3.58±0.07 
ESD  2.10±0.02 2.09±0.04  2.16±0.06 2.19±0.07   2.35±0.02 2.31±0.07 
%FS  35.7±0.85 36.5±1.11  37.1±2.16 35.2±2.33   35.1±0.78 35.0±2.71 
IVSD  0.63±0.02 0.63±0.01  0.73±0.02 0.72±0.02   0.76±0.01 0.77±0.01 
IVSS  0.77±0.03 0.79±0.02  0.86±0.02 0.85±0.02   1.10±0.06 1.06±0.02 
PWD  0.63±0.02 0.63±0.01  0.68±0.03 0.65±0.06   0.71±0.03 0.75±0.03 
PWS  0.79±0.02 0.80±0.02  0.89±0.02 0.88±0.02   0.98±0.05 1.03±0.06 




Legends of supplemental figures 
Supplemental Fig. 1.  Functional expression of SPHK1a in transgenic mice. (A) 
Different mRNA expression patterns of the SPHK1a transgene (indicated by 
arrowheads) in two lines of SPHK1aTG mice, TG(L) and TG(H). Total RNA (15 µg) 
prepared from various organs of TG(L) and TG(H) mice were subjected to Northern 
blot analysis. TG mice of both lineages showed an identical expression pattern for 
endogenous SPHK1a mRNA (arrows) as in WT mice, with high expression levels in the 
lung, spleen, kidney, intestine, uterus, and skin. The results for transient SPHK1a 
overexpression in mouse B16 melanoma cells and parental cells are also shown (right). 
 
Supplemental Fig. 2. TG(H) mice showed normal blood cell count.  Both wild type 
(WT) and TG(H) littermate mice (three mice each) were analyzed for numbers of 
peripheral blood red blood cells (RBC), white blood cells (WBC), lymphocytes 
(Lymph), and platelets (Plt). TG(L) mice showed normal values.  
 
Supplemental Fig. 3. Immunofluorescent staining of SPHK1a (green) in cardiac 
tissues of WT (left panel) and SPHK1-KO (right panel) mice. Cryosections of the 
hearts from wild-type and SPHK1-homozygouslydisrupted (SPHK1-KO) mice were 
CVR-2008-1173R2 
stained with anti-SPHK1-specific antibody as described in the Supplementary Materials 
and Methods. Cell nuclei were stained with DAPI. 
 
Supplemental Fig. 4. Upregulation of embryonic genes and profibrotic genes in 
TG(H) hearts at the ages of 3 and 9 months. (A) Expression of “fetal” genes. Total 
RNA prepared from ventricles of WT and TG(H) mice (n=3 or 4) were analyzed for the 
expression of mRNAs of SPHK1, ANP, BNP, β-MHC, and SKM α-actin by Northern 
blot. GAPDH was used as an internal standard. 
 
Supplemental Fig. 5. Upregulation of the expression of collagen type I α1 and α2 
polypeptides. The homogenates of the hearts from wild-type and SPHK1-TG(H) mice 
were prepared as described in the Supplementary Materials and Methods were analyzed, 
and analyzed Western blotting using specific anti-procollagen type I α1- and 
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